IMBRUVICA is a drug used to treat certain B-cell malignancies (MCL, CLL/SLL, WM, MZL) and chronic graft versus host disease (cGVHD). Since its launch in 2013, IMBRUVICA has received 11 FDA approvals across six disease areas, and was previously approved only for use in adults.

In August 2022, the FDA approved IMBRUVICA as first and inly BTKi treatment for pediatric patients with cGVHD. I supported the team with this pediatric indication launch, leading the art direction on all pediatric materials including website violators and pages, as well as a full redesign of the dosing instructions.